We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Synthetic Probes Used to Image Cell Death

By HospiMedica International staff writers
Posted on 23 Feb 2010
For quite some time, the "Holy Grail” in medical imaging has been the development of an effective technique to image cell death as a way to intervene early in diseases and rapidly determine the effectiveness of treatments. More...
A new study has demonstrated important progress in using a synthetic probe to target dead and dying cells in mammary and prostate tumors in living animals.

The researchers working on the project were from the University of Notre Dame (Notre Dame, IL, USA) and the Washington University School of Medicine (St. Louis, MO, USA). Bradley D. Smith, a professor of chemistry and biochemistry at Notre Dame, points out that the group of researchers had previously discovered that synthetic zinc (II)-dipicolylamine (Zn-DPA) coordination complexes can selectively target the outer surfaces of anionic cell membranes. Furthermore, fluorescent versions of these Zn-DPA complexes act as imaging probes that can distinguish dead and dying mammalian cells from healthy cells in a cell culture and also selectively target bacteria in contaminated samples.

The researchers also recently demonstrated that a fluorescent near-infrared (NIR) probe referred to as PSS-794 can be used to image bacterial infections in mice, indicating that PSS-794 has a notable ability to selectively target anionic cells in living animals.

In the new study, the researchers revealed a significant expansion of the animal imaging capability of PSS-794 by showing that it can target the anionic dead and dying cells within tumors in rat and mouse models. The research is an important step toward the development of optical imaging probes that could determine, noninvasively, the amount and type of cell death in tumors. Such imaging techniques could help clinicians accurately determine the grade of tumors and the stage of cancers, as well as to measure the effectiveness of treatments.

The researchers also believe that analogous probes can be developed that would allow for deep tissue imaging of cancers in humans. Prof. Smith pointed out that although the study focused on mammary and prostate tumors, imaging of cell death is also useful for treatment of numerous conditions, including cardiovascular disease, neurology, renal disease, and even transplant rejection.

The research was published online December 2009 in the Journal of the American Chemical Society (JACS).

Related Links:

University of Notre Dame
Washington University School of Medicine


Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Gas Analyzer
GE SAM
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.